PB1926: REAL-WORLD ERYTHROPOIESIS-STIMULATING AGENT (ESA) TREATMENT PATTERNS AND OUTCOMES AMONG US PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS). (23rd June 2022) - Mukherjee, S.; Zimmerman Savill, K.; Gajra, A.; Kish, J.; Brown-Bickerstaff, C.; Gentile, D.; Falkenstein, A.; Miller, T.; Laney, J.; McBride, A.